The regulation and importance of monocyte chemoattractant protein-1

Vanessa Bianconi, Amirhossein Sahebkar, Stephen Atkin, Matteo Pirro

Research output: Contribution to journalReview article

32 Citations (Scopus)


Purpose of review Monocyte chemoattractant protein (MCP)-1, a chemokine regulating monocyte chemotaxis and T-lymphocyte differentiation by binding to the CC chemokine receptor 2 (CCR2), plays a crucial role in the pathogenesis of inflammatory diseases, atherosclerosis and cancer. This review summarizes the current knowledge on the regulation and importance of the MCP-1/CCR2 axis, focusing on the therapeutic potential of its inhibition. Recent findings Differential modulation of MCP-1 and CCR2 lead to downstream activation pathways, pathogenetic to differing disease conditions characterized by dysregulated monocyte/macrophage tissue recruitment. Pharmacological targeting of the MCP-1/CCR2 axis has led to selective MCP-1/CCR2 antagonists that have now entered phase I/II clinical trials for the treatment of inflammatory diseases, atherosclerosis and cancer. The pleiotropic nonselective MCP-1/CCR2 inhibition by current pharmacological agents is thought to contribute to their anti-inflammatory and antiatherosclerotic effects that is also seen for nutraceutical compounds such as curcumin. Summary MCP-1 has a critical role in regulating chemotaxis both in health and disease, with increasing interest in its pharmacological inhibition. However, the therapeutic efficacy and safety of targeting the MCP-1/CCR2 axis is still in evolution.

Original languageEnglish
Pages (from-to)44-51
Number of pages8
JournalCurrent Opinion in Hematology
Issue number1
Publication statusPublished - 1 Jan 2018



  • atherosclerosis
  • cancer
  • CC chemokine receptor 2
  • inflammation
  • monocyte chemoattractant protein

ASJC Scopus subject areas

  • Hematology

Cite this